Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: gp96 (grp94) is a key downstream chaperone in the endoplasmic reticulum (ER) to mediate unfolded protein response (UPR) and the pathogenesis of multiple myeloma is closely linked to dysregulated UPR. In this study, we aimed to determine the roles of gp96 in the initiation and progression of multiple myeloma in vivo and in vitro. Experimental Design: We generated a mouse model with overexpression of XBP1s and conditional deletion of gp96 in B-cell compartment simultaneously to identify the roles of gp96 in the development of multiple myeloma in vivo. Using a short hairpin RNA (shRNA) system, we silenced gp96 in multiple human multiple myeloma cells and examined the effect of gp96 knockdown on multiple myeloma cells by cell proliferation, cell-cycle analysis, apoptosis assay, immunohistochemistry, and human myeloma xenograft model. The anticancer activity of gp96 selective inhibitor, WS13, was evaluated by apoptosis assay and MTT assay. Results: Genetic deletion of gp96 in XBP1s-Tg mice attenuates multiple myeloma. Silencing of gp96 causes severe compromise in human multiple myeloma cell growth through inhibiting Wnt-LRP-survivin pathway. We also confirmed that knockdown of gp96 decreased human multiple myeloma growth in a murine xenograft model. The targeted gp96 inhibitor induced apoptosis and blocked multiple myeloma cell growth, but did not induce apoptosis in pre-B leukemic cells. We have demonstrated that myeloma growth is dependent on gp96 both genetically and pharmacologically. Conclusions: gp96 is essential for multiple myeloma cell proliferation and survival, suggesting that gp96 is a novel therapeutic target for multiple myeloma. Clin Cancer Res; 19(22); 6242–51. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Iwakoshi, N. N., Lee, A.-H., Vallabhajosyula, P., Otipoby, K. L., Rajewsky, K., & Glimcher, L. H. (2003) · Nature Immunology · doi:10.1038/ni907 · Cited by 880
Ozaki, K., Spolski, R., Ettinger, R., Kim, H.-P., Wang, G., Qi, C.-F., Hwu, P., Shaffer, D. J., Akilesh, S., Roopenian, D. C., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5361 · Cited by 668
Papandreou, I., Denko, N. C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D. E., Bouley, D. M., Offner, F., Niwa, M., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303099 · Cited by 489
Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood · doi:10.1182/blood-2011-07-366633 · Cited by 432 · cited 1×
“XBP1s and downstream ER chaperones are consistently up regulated in myeloma cells in patients (16), inspiring increasing efforts to develop UPRtargeted anti-MM therapy (41-43).”
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
Carrasco, D. R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D. E., Zheng, M., Mani, M., Henderson, J., Pinkus, G. S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.015 · Cited by 414
Self-citationChesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Liu, B., & Li, Z. (2008) · Blood · doi:10.1182/blood-2008-03-143107 · Cited by 129 · cited 5×
“Genetic deletion of gp96 in XBP1s-Tg mice attenuates myeloma Using CD19cre-mediated deletion of gp96, we previously found that gp96 is dispensable for immunoglobulin (Ig) synthesis, Ig assembly, B cell differentiation, plasma cell development and Ig class-switching.(19) It is unclear, however, if gp96 plays important…”
InfluentialSelf-citationWeekes, M. P., Antrobus, R., Talbot, S., Hör, S., Simecek, N., Smith, D. L., Bloor, S., Randow, F., & Lehner, P. J. (2012) · Journal of Proteome Research · doi:10.1021/pr201135e · Cited by 82
Cited by
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
“Other studies showed that overexpressed GRP94 encouraged the growth and metastasis of certain cancers, including hepatocellular carcinoma [225], multiple myeloma [226], ovarian cancer, and inflammatory colon carcinomas [227].”
BackgroundGlucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential
Lee, A. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3701 · Cited by 587
Li, Q., Ma, L., Shen, S., Guo, Y., Cao, Q., Cai, X., Feng, J., Yan, Y., Hu, T., Luo, S., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1271-3 · Cited by 104
Self-citationGP96 is a GARP chaperone and controls regulatory T cell functions
Zhang, Y., Wu, B. X., Metelli, A., Thaxton, J. E., Hong, F., Rachidi, S., Ansa-Addo, E., Sun, S., Vasu, C., Yang, Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79014 · Cited by 95
Self-citationHuck, J. D., Que, N. L., Hong, F., Li, Z., & Gewirth, D. T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.079 · Cited by 73
Self-citation
Metadata
- Authors
- Hua, Y., White-Gilbertson, S., Kellner, J., Rachidi, S., Usmani, S. Z., Chiosis, G., DePinho, R., Li, Z., & Liu, B.
- Venue
- Clinical Cancer Research
- Published
- 2013-11-14
- Volume
- 19
- Issue
- 22
- Pages
- 6242-6251
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2155010407
- Cited by
- 73
- References
- 9
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2083
- The paper
- Hua, Y., White-Gilbertson, S., Kellner, J., Rachidi, S., Usmani, S. Z., Chiosis, G., DePinho, R., Li, Z., & Liu, B. (2013). Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.